Trials / Completed
CompletedNCT02030925
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Ironwood Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IW-3718 | |
| DRUG | Matching Placebo |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-01-09
- Last updated
- 2016-08-01
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02030925. Inclusion in this directory is not an endorsement.